These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34736844)

  • 1. The Accumulation of Gut Microbiome-derived Indoxyl Sulfate and P-Cresyl Sulfate in Patients With End-stage Renal Disease.
    Lin X; Liang W; Li L; Xiong Q; He S; Zhao J; Guo X; Xiang S; Zhang P; Wang H; Ying C; Yao Y; Zuo X
    J Ren Nutr; 2022 Sep; 32(5):578-586. PubMed ID: 34736844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inulin-type fructan intervention restricts the increase in gut microbiome-generated indole in patients with peritoneal dialysis: a randomized crossover study.
    Li L; Xiong Q; Zhao J; Lin X; He S; Wu N; Yao Y; Liang W; Zuo X; Ying C
    Am J Clin Nutr; 2020 May; 111(5):1087-1099. PubMed ID: 31942927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease.
    Nazzal L; Roberts J; Singh P; Jhawar S; Matalon A; Gao Z; Holzman R; Liebes L; Blaser MJ; Lowenstein J
    Nephrol Dial Transplant; 2017 Nov; 32(11):1809-1817. PubMed ID: 28379433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered gut microbiota and gut-derived p-cresyl sulfate serum levels in peritoneal dialysis patients.
    Bao M; Zhang P; Guo S; Zou J; Ji J; Ding X; Yu X
    Front Cell Infect Microbiol; 2022; 12():639624. PubMed ID: 36237423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fecal microbiome and serum concentrations of indoxyl sulfate and p-cresol sulfate in cats with chronic kidney disease.
    Summers SC; Quimby JM; Isaiah A; Suchodolski JS; Lunghofer PJ; Gustafson DL
    J Vet Intern Med; 2019 Mar; 33(2):662-669. PubMed ID: 30561098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study.
    Crespo-Salgado J; Vehaskari VM; Stewart T; Ferris M; Zhang Q; Wang G; Blanchard EE; Taylor CM; Kallash M; Greenbaum LA; Aviles DH
    Microbiome; 2016 Sep; 4(1):50. PubMed ID: 27640125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change.
    Liu Y; Li J; Yu J; Wang Y; Lu J; Shang EX; Zhu Z; Guo J; Duan J
    J Pharm Biomed Anal; 2018 Feb; 149():425-435. PubMed ID: 29169110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the oral adsorbent AST-120 on fecal p-cresol and indole levels and on the gut microbiota composition.
    Sato E; Hosomi K; Sekimoto A; Mishima E; Oe Y; Saigusa D; Ito S; Abe T; Sato H; Kunisawa J; Niwa T; Takahashi N
    Biochem Biophys Res Commun; 2020 May; 525(3):773-779. PubMed ID: 32147096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD.
    Wong J; Piceno YM; DeSantis TZ; Pahl M; Andersen GL; Vaziri ND
    Am J Nephrol; 2014; 39(3):230-237. PubMed ID: 24643131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients.
    Gryp T; Huys GRB; Joossens M; Van Biesen W; Glorieux G; Vaneechoutte M
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor.
    Madero M; Cano KB; Campos I; Tao X; Maheshwari V; Brown J; Cornejo B; Handelman G; Thijssen S; Kotanko P
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):394-402. PubMed ID: 30755453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota as Diagnostic Tools for Mirroring Disease Progression and Circulating Nephrotoxin Levels in Chronic Kidney Disease: Discovery and Validation Study.
    Wu IW; Lin CY; Chang LC; Lee CC; Chiu CY; Hsu HJ; Sun CY; Chen YC; Kuo YL; Yang CW; Gao SS; Hsieh WP; Chung WH; Lai HC; Su SC
    Int J Biol Sci; 2020; 16(3):420-434. PubMed ID: 32015679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
    Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G
    Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis.
    Iguchi A; Yamamoto S; Oda A; Tanaka K; Kazama JJ; Saeki T; Yamazaki H; Ishioka K; Suzutani T; Narita I
    Clin Exp Nephrol; 2020 Aug; 24(8):725-733. PubMed ID: 32285213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.
    Rossi M; Johnson DW; Morrison M; Pascoe EM; Coombes JS; Forbes JM; Szeto CC; McWhinney BC; Ungerer JP; Campbell KL
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):223-31. PubMed ID: 26772193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.
    Lin CJ; Wu V; Wu PC; Wu CJ
    PLoS One; 2015; 10(7):e0132589. PubMed ID: 26173073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synbiotics Alleviate the Gut Indole Load and Dysbiosis in Chronic Kidney Disease.
    Yang CY; Chen TW; Lu WL; Liang SS; Huang HD; Tseng CP; Tarng DC
    Cells; 2021 Jan; 10(1):. PubMed ID: 33435396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD.
    Poesen R; Evenepoel P; de Loor H; Kuypers D; Augustijns P; Meijers B
    Clin J Am Soc Nephrol; 2016 Jul; 11(7):1136-1144. PubMed ID: 27084876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.
    Viaene L; Meijers BK; Bammens B; Vanrenterghem Y; Evenepoel P
    Perit Dial Int; 2014; 34(1):71-8. PubMed ID: 24179107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.